maverick_1,
I use a cheat sheet of sorts. I try to stay ahead with the science which tells me where this will eventually get to if it can survive, which due diligence on Linda confirmed would happen, but watch the charts for the cycles for when to buy. NWBO earned my support by choice through the ups and downs with cost averaging. Low cost basis now. Enrolling 331 vs 348 sealed the deal because I was certain they left out German SOC patients. That is something they could have cleared up but never did by choice obviously. They have 4 year plus data now for comparative purposes and they already showed us the improving blinded outcomes. Mr. Pearlmutter is a "Johnny come lately" for me. Triozi et al set up the scientific premise/basis for expected long term success. Knowing Linda's character and tenacity was the reason to expect it to get there. Best wishes.